Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible health research updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.
Today in one sentence: A study found monthly HIV injections can keep treatment on track for people who miss pills, a glaucoma coaching program helped patients use eye drops more, scientists flagged a new target that may slow liver scarring, a mouse study showed a gene tweak that made hearts more injury-resistant, and the FDA announced a new lung cancer drug approval through its priority voucher pilot program.
Good news: Monthly HIV shots helped people who struggle to take daily pills keep treatment working better. That could mean fewer people have the virus “bounce back.”
Market readiness: 🙂🙂🙂🙂🙂 (These long-acting injections are already available in the US; this study supports using them for people who have trouble taking pills every day.)
Good news: A simple coaching program helped people with glaucoma use their eye drops more often. Better drop use can help protect eyesight.
Market readiness: 🙂🙂🙂🙂🙂 (This is a care program, not a new drug; eye clinics could start using this approach now.)
Good news: A medicine helped bone-making cells work better and helped a child’s long-lasting bone break finally heal. This could lead to better care for hard-to-heal fractures in this rare disease.
Market readiness: 🙂🙂🙂🙂 (The drug is already FDA-approved for another condition, but using it for fracture healing is new and would need more studies before it becomes routine care.)
Good news: Researchers found a new “switch” (LARP6) that helps cause liver scarring. Turning it down reduced scarring in lab-grown human liver tissue, which could help future liver-fibrosis treatments.
Market readiness: 🙂 (This is still early lab research; it has not reached human clinical trials yet.)
Good news: In mice, changing a gene pathway made hearts much more protected after a heart attack and against damage from a high-fat diet. It points to a new way to protect hearts in the future.
Market readiness: 🙂 (This is a mouse genetics finding; it’s not a treatment you can get yet.)
Good news: The FDA announced a new lung cancer drug approval, which can give some patients another treatment option right now.
Market readiness: 🙂🙂🙂🙂🙂 (This is an FDA approval announcement, meaning the treatment can be prescribed in the US.)
Thank you for taking the time to take care of yourself and your loved ones.
